Collaboration Agreement [Abstract] Collaboration Agreement Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Schedule of Research and Development Arrangement, Contract to Perform for Others [Table] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] PDGFR-beta outside the US PDGFR-beta outside the US [Member] PDGFR-beta outside the US Ang2 Antibody [Member] Ang2 Antibody [Member] Ang2 Antibody [Member] Collaboration Agreements [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Maximum percentage of outstanding shares that may be acquired, under 'standstill' provisions Maximum percentage of outstanding shares that may be acquired, under 'standstill' provisions The maximum percentage of outstanding shares of the Company's Class A Stock and Common Stock that may be acquired under the 'standstill' provisions, in effect after the specified date. Percentage of global development cost to be paid by the collaboration partner under the collaboration Percentage of global development cost to be paid by the collaboration partner under the collaboration Percentage of global development cost to be paid by the collaboration partner under the collaboration Percentage of development cost for the territory outside the United States to be paid for under the collaboration Percentage of development cost for the territory outside the United States previously required to be paid for under the collaboration Percentage of development cost for the territory outside the United States previously required to be paid for under the collaboration. Deferred Revenue, Additions Deferred Revenue, Additions Recognition of Deferred Revenue Recognition of Deferred Revenue Future development milestone payment the Company is eligible to receive Future Development Milestone Payment Companyis Eligible to Receive Future Development Milestone Payment Companyis Eligible to Receive Revenue Recognition, Milestone Method, Revenue Recognized Revenue Recognition, Milestone Method, Revenue Recognized Accounts receivable from Bayer Accounts and Notes Receivable, Net Proceeds from Collaborators Proceeds from Collaborators Inventory Disclosure [Abstract] Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Deferred Revenue Disclosure [Abstract] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Domain] Deferred Revenue [Domain] Received or receivable from Sanofi Collaboration Agreement with Sanofi [Member] Collaboration agreement with Sanofi. Received or receivable from Bayer HealthCare Collaboration Agreement with Bayer HealthCare LLC [Member] Collaboration agreement with Bayer HealthCare LLC. Mitsubishi Tanabe Pharma Corporation (MTPC) [Member] Mitsubishi Tanabe Pharma Corporation (MTPC) [Member] Mitsubishi Tanabe Pharma Corporation (MTPC) [Member] Teva Pharmaceuticals [Member] Teva Pharmaceuticals [Member] Teva Pharmaceuticals Collaboration Agreement Received for technology license agreement Nonsoftware License Arrangement [Member] Other Other Deferred Revenue Agreements [Member] Other category of deferred revenue agreements not otherwise specified in the taxonomy. Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Current portion: Deferred Revenue and Credits, Current [Abstract] Deferred revenue, current portion Deferred Revenue, Current Deferred revenue - other, current portion Deferred Revenue, Excluding Amounts from Related Party, Current The carrying amount of other consideration received or receivable as of the balance sheet date that were not recognized as revenue, and which are expected to be recognized as revenue within one year. Long-term portion: Deferred Revenue and Credits, Noncurrent [Abstract] Deferred revenue, long-term portion Deferred Revenue, Noncurrent Deferred revenue - other Deferred Revenue, Excluding Amounts from Related Party, Non-current The noncurrent portion of other deferred revenue as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Income Tax Disclosure [Abstract] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule Of Unrecognized Tax Benefits Roll Forward Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Warrant Warrant [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Class A Common Class A [Member] Common Stock Common Stock [Member] Restricted Stock [Member] Restricted Stock [Member] Equity Components [Axis] Equity Component [Domain] Additional Paid-in Capital Additional Paid-in Capital [Member] Retained Earnings (Accumulated Deficit) Retained Earnings [Member] Treasury Stock Treasury Stock [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance Stockholders' Equity Attributable to Parent Balance (shares) Shares, Outstanding Issuance of Common Stock in connection with exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Issuance of Common Stock in connection with exercise of stock options (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Common Stock tendered upon exercise of stock options in connection with employee tax obligations Adjustments Related to Tax Withholding for Share-based Compensation Adjustments related to tax withholding for share based compensation, restricted stock Adjustments related to tax withholding for share based compensation, restricted stock Adjustments related to tax withholding for share based compensation, restricted stock Common Stock tendered upon exercise of stock options in connection with employee tax obligations (in shares) Shares Paid for Tax Withholding for Share Based Compensation Issuance of Common Stock in connection with conversion of convertible senior notes Stock Issued During Period, Value, Conversion of Convertible Securities Issuance of Common Stock in connection with conversion of convertible senior notes (in shares) Debt Conversion, Converted Instrument, Shares Issued Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution Stock Issued During Period, Value, Employee Benefit Plan Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution (shares) Stock Issued During Period, Shares, Employee Benefit Plan Issuance of restricted Common Stock under Long-Term Incentive Plan Stock Issued During Period, Value, Restricted Stock Award, Gross Issuance of restricted Common Stock under Long-Term Incentive Plan (shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Conversion of Class A Stock to Common Stock (shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Stock-based compensation charges Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Excess tax benefit from stock-based compensation Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net Acquisition of Common Stock in connection with exercise of convertible note hedges Treasury Stock, Value, Acquired, Cost Method Acquisition of Common Stock in connection with exercise of convertible note hedges (in shares) Treasury Stock, Shares, Acquired Reduction of warrants Adjustments to Additional Paid in Capital, Other Reclassification of warrant liability Maximum amount of warrant payable Maximum warrant payment amount pursuant to the agreement. Reduction of equity component of convertible senior notes Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments Net income Net Income (Loss) Attributable to Parent Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax Balance Balance (shares) Deferred Revenue Deferred Revenue Disclosure [Text Block] Payables and Accruals [Abstract] Accounts Payable and Accrued Expenses Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Earnings Per Share [Abstract] Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities Interest on Convertible Debt, Net of Tax Net Income (Loss) Attributable to Parent, Diluted Net Income (Loss) Attributable to Parent, Diluted Effect of dilutive securities: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Weighted average shares outstanding - basic Weighted Average Number of Shares Outstanding, Basic Effect of dilutive securities (in shares): Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract] Stock options Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Restricted stock Incremental Common Shares Attributable To Nonvested Restricted Shares Nonvested equity-based payment awards that result in incremental common shares. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Warrants Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Dilutive potential shares Weighted Average Number Diluted Shares Outstanding Adjustment Weighted average shares - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Earnings Per Share, Basic and Diluted [Abstract] Net income per share - basic (in USD per shares) Earnings Per Share, Basic Net income per share - diluted (in USD per shares) Earnings Per Share, Diluted Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Stock options Employee Stock Option [Member] Restricted stock Convertible senior notes Convertible Debt Securities [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Weighted average number of shares Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Statement of Financial Position [Abstract] Class A Stock Common Stock ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Marketable securities Marketable Securities, Current Accounts receivable - trade, net Accounts Receivable, Net, Current Accounts receivable from Sanofi Accounts Receivable, Related Parties, Current Inventories Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Marketable securities Marketable Securities, Noncurrent Property, plant, and equipment, net Property, Plant and Equipment, Net Deferred tax assets Deferred Tax Assets, Net, Noncurrent Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES and STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Capital and facility lease obligations Capital and facility lease obligations, current Amount of capital and facility lease obligation due within one year or the normal operating cycle, if longer. Deferred revenue from Sanofi, current portion Deferred Revenue From Related Party Current The current portion of deferred revenue from related parties as of balance sheet date. Current deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Capital and facility lease obligations, noncurrent Capital and facility lease obligations, noncurrent Represents the noncurrent portion of a lease liability Deferred revenue from Sanofi Deferred Revenue From Related Party Noncurrent The noncurrent portion of deferred revenue from related parties as of balance sheet date. Noncurrent deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Other long term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 12) Commitments and Contingencies Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred Stock Preferred Stock, Value, Issued Common stock Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Retained earnings Retained Earnings (Accumulated Deficit) Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Treasury Stock Treasury Stock, Value Total stockholders' equity Total liabilities and stockholders' equity Liabilities and Equity Derivative Instruments and Hedging Activities [Abstract] Derivative Instruments and Hedging Activities [Abstract] Derivative [Table] Derivative [Table] Energy [Axis] Energy [Axis] Energy [Domain] Energy [Domain] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Position [Axis] Position [Axis] Position [Domain] Position [Domain] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Derivative [Line Items] Derivative [Line Items] Derivative Instruments and Hedging Activities Disclosure [Text Block] Derivative Instruments and Hedging Activities Disclosure [Text Block] Statement of Comprehensive Income [Abstract] Statement [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Income Statement [Abstract] Income Statement [Abstract] Revenues: Revenues [Abstract] Net product sales Sales Revenue, Goods, Net Sanofi collaboration revenue Revenue from Related Parties Bayer collaboration revenue Other Collaboration Revenue Revenue realized from sharing of profits/losses on commercialized products, reimbursement of research and development expenses, and other transactions with our collaborator Bayer during the period. Other revenue Other Revenue, Net Total revenues Revenues Expenses: Costs and Expenses [Abstract] Research and development Research and Development Expense Selling, general, and administrative Selling, General and Administrative Expense Cost of goods sold Cost of Goods Sold Cost of collaboration and contract manufacturing Cost of manufacturing Total cost related to third-party royalties the Company is obligated to pay based on sales of commercial product by the Company’s collaborators, as well as costs in connection with producing commercial supplies for the Company’s collaborators and others. Total expenses Costs and Expenses Income from operations Operating Income (Loss) Other income (expense): Nonoperating Income (Expense) [Abstract] Other income (expense), net Other Nonoperating Income (Expense) Interest expense, net Interest Income (Expense), Nonoperating, Net Total other income (expense) Nonoperating Income (Expense) Income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income tax expense Income Tax Expense (Benefit) Net income Net income per share - basic Net income per share - diluted Weighted average shares outstanding - basic Weighted average shares outstanding - diluted Statements of Comprehensive Income Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Unrealized (loss) gain on marketable securities Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Unrealized gain on cash flow hedges Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Net Product Sales Product Sales and Concentration Risk [Text Block] Product Sales and Concentration Risk Disclosure [Text Block] Investments, Debt and Equity Securities [Abstract] Available-for-sale Securities Available-for-sale Securities [Table Text Block] Marketable Securities, Based on Contractual Maturity Dates Investments Classified by Contractual Maturity Date [Table Text Block] Fair Value and Unrealized Losses of Marketable Securities Schedule of Unrealized Loss on Investments [Table Text Block] Quarterly Financial Information Disclosure [Abstract] Effect of Fourth Quarter Events [Table] Effect of Fourth Quarter Events [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] 2017 Tax Cut and Jobs Act [Member] 2017 Tax Cut and Jobs Act [Member] 2017 Tax Cut and Jobs Act Adjustments for Error Corrections [Axis] Adjustments for Error Corrections [Axis] Adjustments for Error Correction [Domain] Adjustments for Error Correction [Domain] Tarrytown lease transaction [Member] Tarrytown lease transaction [Member] Tarrytown lease transaction [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-09 [Member] Accounting Standards Update 2016-09 [Member] Equity Components [Axis] Equity Component [Domain] New Accounting Pronouncement, Early Adoption [Axis] New Accounting Pronouncement, Early Adoption [Axis] New Accounting Principles, Early Adoption [Domain] New Accounting Principles, Early Adoption [Domain] New Accounting Pronouncement, Early Adoption, Effect [Member] New Accounting Pronouncement, Early Adoption, Effect [Member] Ang2 Ang2 [Member] Ang2 [Member] Research and Development Arrangement Contract to Perform for Others by Product [Axis] Research and Development Arrangement Contract to Perform for Others by Product [Axis] Research and Development Arrangement Contract to Perform for Others by Product [Axis] Research and Development Arrangement Contract to Perform for Others by Product [Domain] Research and Development Arrangement Contract to Perform for Others by Product [Domain] [Domain] for Research and Development Arrangement Contract to Perform for Others by Product [Axis] Antibody Collaboration Antibody Collaboration [Member] In November 2007, the Company entered into a global, strategic collaboration (the Antibody Collaboration) with Sanofi to discover, develop, and commercialize fully human monoclonal antibodies. Quarterly Financial Information Disclosure [Line Items] Effect of Fourth Quarter Events [Line Items] Revenues Substantive milestone payment Out of period adjustment Out of period adjustment Loss on extinguishment of debt related to the March 3, 2017 lease transaction, and a corresponding decrease to property, plant, and equipment. Remeasurement of Deferred Tax Assets due to US Tax Reform Provisional charge for re-measurement of U.S. deferred tax assets due to US Tax Reform Provisional charge recorded during Q4 2017 for the remeasurement of U.S. deferred tax assets upon the enactment of Tax Cut and Jobs Act Income Tax Expense (Benefit) Excess Tax Benefit from Share-based Compensation, Financing Activities Excess Tax Benefit from Share-based Compensation, Financing Activities Accounting Policies [Abstract] Consolidation Consolidation, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Marketable Securities Marketable Securities, Available-for-sale Securities, Policy [Policy Text Block] Accounts Receivable - Trade Trade and Other Accounts Receivable, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Property, Plant and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Revenue Recognition - Product Revenue Revenue Recognition, Sales of Goods [Policy Text Block] Revenue Recognition - Collaboration Revenue Collaborative Arrangement, Accounting Policy [Policy Text Block] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Stock-based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Per Share Data Earnings Per Share, Policy [Policy Text Block] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Recently Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Fair Value Transfer Fair Value Transfer, Policy [Policy Text Block] Legal Costs Legal Costs, Policy [Policy Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Scenario [Axis] Minimum Minimum [Member] Maximum Maximum [Member] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] PD-1 [Member] PD-1 [Member] Programed Cell Death protein 1, or PD-1 ("REGN2810") Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] IO Agreement [Member] IO Agreement [Member] IO Agreement Immuno-oncology Agreement [Member] Immuno-oncology Agreement [Member] Immuno-oncology Agreement Sanofi Sanofi [Member] Information related to Sanofi. ZALTRAP Agreement Aflibercept Agreement [Member] In September 2003, the Company entered into a collaboration agreement (the Aflibercept Agreement) with Aventis Pharmaceuticals Inc. (predecessor to Sanofi), to jointly develop and commercialize aflibercept. IO Discovery Agreement [Member] IO Discovery Agreement [Member] In July 2015, the Company entered into a collaboration agreement (Immuno-Oncology agreement) with Sanofi, to jointly develop and commercialize Immuno-Oncology programs. IO License and Collaboration Agreement [Member] IO License and Collaboration Agreement [Member] In July 2015, the Company entered into a Immuno-oncology License and Collaboration Agreement (the "IO License and Collaboration Agreement") with Sanofi, to jointly develop and commercialize Immuno-oncology products. Collaboration Agreement with Sanofi Contingent reimbursement obligation Contingent reimbursement obligation The Company's total contingent reimbursement obligation to its collaboration partner for development expenses previously funded by its collaboration partner. Common Stock, shares issued (in shares) Common Stock, Shares, Issued Net profit (loss) from commercialization of products under collaboration agreement Net profit (loss) from commercialization of products under collaboration agreement Our share of profits/losses related to commercialization of products by our collaborator based on sales outside the United States. Under the terms of our collaboration agreement, we share profits/losses with our collaborator on commercialization of products. Research and Development Arrangement, Contract to Perform for Others, Compensation Earned Research and Development Arrangement, Contract to Perform for Others, Compensation Earned Contracts Revenue Contracts Revenue License agreement term License agreement term Potential agreement term, from the effective date of agreement. Levels of twelve month sales at which sales milestone payments would be received Levels of twelve month sales at which sales milestone payments would be received Aggregate amount of twelve month sales upon which sales milestone would be received. Deferred Revenue, Revenue Recognized Deferred Revenue, Revenue Recognized Research and Development Expense Collaborative Arrangement, Purchase Price, Percentage of Net Product Sales Collaborative Arrangement, Purchase Price, Percentage of Net Product Sales The percentage of net sales of the product the Company will supply the product to MTPC (subject to adjustment in certain circumstances). Collaborative Arrangement, Additional Eligible Aggregate Payments Collaborative Arrangement, Additional Eligible Aggregate Payments The aggregate amount of additional payments the Company is entitled to receive upon the achievement of specified annual net sales amounts. Deferred Revenue, Additions Aggregate future development milestone payments the Company is eligible to receive Aggregate future development milestone payments the Company is eligible to receive Aggregate future development milestone payments the Company is eligible to receive. Upfront Payment Made Upfront Payment Made Upfront payment made under a collaboration agreement Potential future R&D expenses Potential future R&D expenses The total potential amount of research and development expenses the Company may pay to identify and validate potential immuno-oncology targets and develop therapeutic antibodies against such targets through clinical proof-of-concept. Contingent payments Company could receive Contingent payments Company could receive The amount of contingent payments the Company is entitled to receive related to development and other milestones achieved by MTPC. Maximum amount of shared development costs Maximum amount of shared development costs The maximum amount of shared development expenses for PD-1. Maximum shares the collaborator could sell Maximum shares the collaborator could sell Maximum shares the collaborator could sell through September 30, 2020. Increase amount of shared development costs Increase amount of shared development costs Increase amount of shared development costs Revenue from Related Parties Revenue based on percentage of annual sales in Japan Revenue based on percentage of annual sales in Japan The percentage on annual sales in Japan that the Company is entitled to receive, subject to certain potential adjustments. Percentage of repayment of development balance out of profits Percentage of repayment of development balance out of profits Percentage of repayment of development balance out of profits under the collaboration agreement. Minimum advance notice required to terminate collaboration agreement Minimum advance notice required to terminate collaboration agreement The minimum advance notice required of the collaborating party to terminate the agreement without cause. Annual funding maximum of research activities per amended agreement Annual funding maximum of research activities per amended agreement The maximum annual amount of funding for research activities through 2017 per the amended agreement. Funding Maximum of Research Activities Per Agreement Funding Maximum of Research Activities Per Agreement The maximum amount of cost reimbursement the Company will receive, subject to certain annual limits. Additional years to extend the agreement Additional years to extend the agreement Additional years to extend the agreement Percentage of Trial Costs borne by collaborating party Percentage of Trial Costs borne by collaborating party The percentage of subsequent Shared Phase 3 Trial costs borne by the collaborating party upon receipt of the first positive Phase 3 trial results for a co-developed drug candidate. Percentage of Trial Costs borne by entity Percentage of Trial Costs borne by entity The percentage of subsequent Shared Phase 3 Trial costs borne by the Company upon receipt of the first positive Phase 3 trial results for a co-developed drug candidate. Percentage of trial costs to be reimbursed due to profitability of agreement Percentage of trial costs to be reimbursed due to profitability of agreement The percentage of Shared Phase 3 trial costs to be reimbursed due to profitability of agreement. Excess Share of profit not required to to be applied to reimburse development cost Excess Share of profit not required to to be applied to reimburse development cost The excess percentage of profits from collaboration not required to be used to reimburse development cost in any calendar quarter. Starting share of profits outside the United States, based on sales, for collaborating party Starting share of profits outside the United States, based on sales, for collaborating party On a sliding scale, this element represents the starting share of profits outside the United States, based on sales, for the collaborating party. Starting share of profits outside the United States, based on sales, for Company Starting share of profits outside the United States, based on sales, for Company On a sliding scale, this element represents the starting share of profits outside the United States, based on sales, for the Company. Ending share of profits outside the United States, based on sales, for collaborating party Ending share of profits outside the United States, based on sales, for collaborating party On a sliding scale, this element represents the ending share of profits outside the United States, based on sales, for the collaborating party. Ending share of profits outside the United States, based on sales, for Company Ending share of profits outside the United States, based on sales, for Company On a sliding scale, this element represents the ending share of profits outside the United States, based on sales, for the Company. Share of losses outside the United States, for collaborating party Share of losses outside the United States, for collaborating party This element represents the share of losses outside the United States for the collaborating party. Share of losses outside the United States, for Company Share of losses outside the United States, for Company This element represents the share of losses outside the United States for the Company. Maximum amount of sales milestone payments if total sales achieve specific levels Maximum amount of sales milestone payments if total sales achieve specific levels The maximum amount of sales milestone payments the Company is eligible to receive when and if total annual sales achieve certain specified levels. Starting specified levels of annual sales at which sales milestone payments may be received Starting specified levels of annual sales at which sales milestone payments may be received The starting specified levels of total annual sales within the MTPC Territories at which the Company is eligible to receive additional payments. Period for Achieving Sales Target for Milestone Payment, Rolling Basis Period for Achieving Sales Target for Milestone Payment, Rolling Basis Period for Achieving Sales Target for Milestone Payment, Rolling Basis Percentage of aggregate net sales to be paid by the related party in such calendar year Percentage of aggregate net sales to be paid by the related party in such calendar year Percentage of aggregate net sales to be paid by the related party in such calendar year. Period of Notice to Opt Out of Further Development and or Commercialization Period of Notice to Opt Out of Further Development and or Commercialization The period of notice (in months) for either party under the agreement to opt-out of further development and/or commercialization of each antibody product which enters development. Other Research and Development Expense Other Research and Development Expense Other Revenue, Net Payments to Acquire Marketable Securities Payments to Acquire Marketable Securities Proceeds from License Fees Received Proceeds from License Fees Received Recognition period for advance payment Recognition period for advance payment The revenue recognition period (in years) of the up-front payment the Company received under the terms of the amended licensing agreement. This payment was deferred upon receipt and will be recognized as revenue ratably, beginning in mid-2011. Future payment to be made under terms of amended licensing agreement Future payment to be made under terms of amended licensing agreement The amount of future payment to be made to the Company in June 2018 under the terms of the amended licensing agreement, unless the license agreement is terminated prior to that date. Period over which we have obligation Period over which we have obligation Period over which the Company has the obligation to provide research funding Number of days of advance written notice to terminate agreement Number of days of advance written notice to terminate agreement The number of days the licensee must provide advance written notice in order to terminate the licensing agreement. Related Party Transaction, Other Revenues from Transactions with Related Party Related Party Transaction, Other Revenues from Transactions with Related Party Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Executive Stock Purchase Plan [Abstract] Executive Stock Purchase Plan [Abstract] Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table] Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table] Employee Stock Ownership Plan (ESOP) Disclosures, by Plan [Axis] Employee Stock Ownership Plan (ESOP) Name [Axis] Employee Stock Ownership Plan (ESOP), Plan [Domain] Employee Stock Ownership Plan (ESOP), Plan [Domain] Employee Stock Ownership Plan (ESOP) Disclosures [Line Items] Employee Stock Ownership Plan (ESOP) Disclosures [Line Items] Collaboration Agreement with Bayer HealthCare LLC EYLEA EYLEA [Member] EYLEA [Member] Ang2 antibody and PDGFR-beta antibody Ang2 antibody and PDGFR-beta antibody [Member] Ang2 antibody and PDGFR-beta antibody Royalty rate minimum Royalty rate minimum The minimum royalty rate to be paid to the Company under the agreements. Royalty rate maximum Royalty rate maximum The maximum royalty rate to be paid to the Company under the agreements. Other Collaboration Revenue Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Legal Costs, Policy [Policy Text Block] Loss Contingency, Damages Sought, per unit produced. Loss Contingency, Damages Sought, per unit produced. Loss Contingency, Damages Sought, per unit produced. Loss Contingency, Damages Sought, Value Loss Contingency, Damages Sought, Value Raw materials Inventory, Raw Materials, Net of Reserves Work in process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Deferred costs Other Inventory, Net of Reserves Total Inventories Receivables and Revenues [Abstract] Receivables and Revenues [Abstract] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Adicet Bio [Member] Adicet Bio [Member] Adicet Bio [Member] Decibel Therapeutics [Member] Decibel Therapeutics [Member] Decibel Therapeutics [Member] Payment for preferred shares Payment for preferred shares Payment to acquire preferred shares Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Long-Term Incentive Plan 2000 Long-Term Incentive Plan 2000 [Member] Long-Term Incentive Plan 2000 [Member] Long-Term Incentive Plan 2014 Long-Term Incentive Plan 2014 [Member] Long-Term Incentive Plan 2014 Amended & Restated Long-Term Incentive Plan 2014 Amended & Restated Long-Term Incentive Plan 2014 [Member] Amended & Restated Long-Term Incentive Plan 2014 Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Stock options Phantom stock Phantom Share Units (PSUs) [Member] Stock Appreciation Rights (SARs) [Member] Stock Appreciation Rights (SARs) [Member] Non-performance based stock options Non-Performance Based Stock Options [Member] A stock option whose vesting is not contingent upon performance achievements. Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of shares authorized for issuance Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Additional Shares Registered Additional Shares Registered Additional shares registered under the Amended and Restated 2014 Long-Term Incentive Plan. Common Stock, Par or Stated Value Per Share Common Stock, Par or Stated Value Per Share Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Maximum term of awards Share Based Compensation Arrangement By Share Based Payment Award Expiration The term (in years) when the equity-based award expires as specified in the award agreement. Period within vesting date that awards may be received Share Based Compensation Arrangement By Share Based Payment Award Period From Vesting Date Awards May Be Received The period (in days) from the vesting date during which the Participant has the right to receive, an amount, in cash and/or shares of the Company's Common Stock as determined by the Committee, equal to the sum of the fair market value of a share of Common Stock on the date such share of Phantom Stock vests and the aggregate amount of cash dividends paid with respect to a share of Common Stock during the period from the grant date of the share of Phantom Stock to the date on which the share vests. Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Number of shares available for future grants Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of shares outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of shares granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Number of shares forfeited Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Number of shares expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Number of shares exercised Number of shares outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted average exercise price - outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted average exercise price - granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average exercise price - forfeited Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted average exercise price - expired Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Weighted average exercise price - exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted average exercise price - outstanding at end of period Weighted average remaining contractual term (in years) - outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Instrinsic value - outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Number of shares vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Weighted average execise price - vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted average remaining contractual term - vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Intrinsic value - vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Number of shares exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted average exercise price - exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted average remaining contractual term - exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Intrinsic value - exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Total intrinsic value - of stock options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Employee Service Share-based Compensation, Aggregate Disclosures [Abstract] Employee Service Share-based Compensation, Aggregate Disclosures [Abstract] Exercise Price Equal to Market Price [Abstract] Exercise price equal to Market Price [Abstract] -- None. No documentation exists for this element. -- Number of Options Granted (shares) Weighted Average Exercise Price (dollars per share) Weighted Average Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Non-cash stock-based compensation expense Allocated Share-based Compensation Expense Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount Unrecognized stock-based compensation cost, net of estimated forfeitures Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Weighted average period for recognition of total unrecognized compensation expense (in years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected lives from grant date Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Number of shares outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of shares granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Number of shares vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Number of shares forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of shares outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Weighted average grant date fair value at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted average grant date fair value - granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value - vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted average grant date fair value - forfeited Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share Weighted average grant date fair value at end of period Schedule of Available-for-sale Securities [Table] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Corporate bonds Corporate Bond Securities [Member] U.S. government and government agency obligations US Treasury and Government [Member] Municipal Bonds [Member] Municipal Bonds [Member] Commercial Paper [Member] Commercial Paper [Member] Certificates of Deposit [Member] Certificates of Deposit [Member] Equity Securities [Member] Equity Securities [Member] Classification of Investment [Axis] This element represents the general categories of investments, which may be classified as Unrestricted or Restricted. Classification of Investment [Domain] Provides general categories of investments for which information is required or determined to be disclosed. Unrestricted Unrestricted [Member] Investments whose use is not restricted in whole or in part, by contractual agreements or regulatory requirements. Schedule of Available-for-sale Securities [Line Items] Other than Temporary Impairment Losses, Investments Other than Temporary Impairment Losses, Investments Amortized Cost Basis Available-for-sale Securities, Amortized Cost Basis Unrealized Gains Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Unrealized (Losses) Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Total fair value of available-for-sale marketable securities Available-for-sale Securities Available-for-sale Securities, Debt Maturities, Fair Value [Abstract] Available-for-sale Securities, Debt Maturities, Fair Value, Fiscal Year Maturity [Abstract] Maturities within one year Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value Maturities after one year through five years Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value Total Available-for-sale Securities, Debt Securities Continuous Unrealized Loss Position, Fair Value [Abstract] Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Abstract] Fair Value - Less than 12 Months Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Fair Value - 12 Months or Greater Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value Fair Value - Total Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value Continuous Unrealized Loss Position, Aggregate Losses [Abstract] Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss [Abstract] Unrealized Loss - Less than 12 months Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Unrealized Loss- 12 Months or Greater Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Unrealized Loss - Total Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss Realized Gain (Loss) on Marketable Securities, Cost Method Investments, and Other Investments Realized Gain (Loss) on Marketable Securities, Cost Method Investments, and Other Investments Technology Licensing Agreements [Abstract] Technology Licensing Agreements [Abstract] Scenario, Forecast [Member] Scenario, Forecast [Member] Aflibercept Agreement [Member] Nonsoftware License Arrangement [Member] License Agreement with Astellas Pharma Inc. License Agreement with Astellas Pharma Inc [Member] Category of deferred revenue by arrangement wherein certain rights are granted to Astellas Pharma Inc. under a license agreement to exploit the Company's technology, under which fees received are taken into income as revenue recognition criteria are met. Non-exclusive license agreement term Advance payment received due to amended licensing agreement Collaboration and License Agreements Collaborative Arrangement Disclosure [Text Block] Accounts Payable and Accrued Liabilities, Current [Abstract] Accounts payable Accounts Payable, Trade, Current Accrued payroll and related costs Employee-related Liabilities, Current Accrued clinical trial expense Accrued Clinical Trial Expense Current Carrying value as of the balance sheet date of obligations incurred (and for which invoices have not been received) in connection with clinical trials. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued sales-related charges, deductions and royalties Accrued sales-related charges, deductions and royalties Carrying value as of the balance sheet date of sales-related charges, deductions and obligations incurred through that date and accrual for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Taxes Payable, Current Taxes Payable, Current Other accrued expenses and liabilities Other Accrued Liabilities, Current Accounts payable and accrued expenses Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Treasury stock, shares outstanding (in shares) Treasury Stock, Shares Common Stock, par value (in dollars per share) Common Stock, shares authorized (in shares) Common Stock, Shares Authorized Common Stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Schedule of Facility Leases [Table] Schedule of Facility Leases [Table] -- None. No documentation exists for this element. -- Facility Lease Obligations [Axis] Facility Lease Obligations [Axis] Facility lease obligations, by facility. Facility Lease Obligations, Name [Domain] Facility Lease Obligations, Name [Domain] The name of the facilities leased under facility lease obligations. Schedule of Facility Leases [Line Items] Schedule of Facility Leases [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. 2018 Capital and facility leases, future minimum payments due, next twelve months Capital and facility leases, future minimum payments due, next twelve months 2019 Capital and facility leases, future minimum payments due in two years Capital and facility leases, future minimum payments due in two years 2020 Capital and facility leases, future minimum payments due in three years Capital and facility leases, future minimum payments due in three years 2021 Capital and facility leases, future minimum lease payments due in four years Capital and facility leases, future minimum lease payments due in four years 2022 Capital and facility leases, future minimum lease payments due in five years Capital and facility leases, future minimum lease payments due in five years Thereafter Capital and facility leases, future minimum lease payments due thereafter Capital and facility leases, future minimum lease payments due thereafter Total Capital and facility leases, future minimum lease payments due Capital and facility leases, future minimum lease payments due Facility lease obligations [Abstract] Facility lease obligations [Abstract] -- None. No documentation exists for this element. -- Commitments under facility leases [Abstract] Facility Leases, Future Minimum Payments Due [Abstract] -- None. No documentation exists for this element. -- Research Collaboration and Licensing Arrangements [Table] Research Collaboration and Licensing Arrangements [Table] -- None. No documentation exists for this element. -- Research Collaboration and Licensing Agreements [Axis] Research Collaboration and Licensing Agreements [Axis] The research collaboration and licensing agreements entered into. Research Collaboration and Licensing Agreements [Domain] Research Collaboration and Licensing Agreements [Domain] Research collaboration and licensing agreements, by name. Agreements with Royalty Provisions Royalty Agreement Terms [Member] Research Collaboration and Licensing Arrangements [Line Items] Research Collaboration and Licensing Arrangements [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Royalty expense Royalty Expense Commitments and Contingencies Commitments Disclosure [Text Block] Interest Rate Swap [Member] Interest Rate Swap [Member] Interest Rate Cap [Member] Interest Rate Cap [Member] Gain (Loss) on Interest Rate Cash Flow Hedge Ineffectiveness Gain (Loss) on Interest Rate Cash Flow Hedge Ineffectiveness Derivative, Notional Amount Derivative, Notional Amount Document And Entity Information [Abstract] -- None. No documentation exists for this element. -- Entities [Table] Entity Information [Line Items] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Entity Public Float Entity Public Float Equity [Abstract] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Bayer Collaboration Agreement - PDGFR-beta outside the US Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Convertible senior notes Convertible Debt [Member] Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Common Stock, voting rights Common Stock, Voting Rights Number of shares of Common Stock purchased Number of newly issued shares purchased The number of newly issued shares of the Company's Common Stock purchased in connection with the Sanofi collaboration agreement. Number of demand rights to require the Company to conduct registered underwritten public offering Number of demand rights to require the Company to conduct registered underwritten public offering Number of demand rights to require the Company to use all reasonable efforts to conduct registered underwritten public offering with respect to shares of the Company's Common Stock held by Sanofi from time to time. Percentage Of Outstanding Shares Or Voting Rights Under Amended Investor Agreement Percentage Of Outstanding Shares Or Voting Rights Under Amended Investor Agreement The percentage of the then outstanding shares or voting rights of the Company's Class A Stock and Common Stock, which if a stock issuance equals or exceeds such amount, the collaborator has not contractually agreed to vote, and cause its affiliates to vote, either as recommended by the Company's board of directors or proportionally with the votes cast by the Company's other shareholders. Percentage Of Outstanding Shares that the Company is required to appoint an individual agreed upon by the Company and the Collaborator to the Company's board of directors Percentage Of Outstanding Shares that the Company is required to appoint an individual agreed upon by the Company and the Collaborator to the Company's board of directors The percentage outstanding shares that the Company is required to appoint an individual agreed upon by the Company and the collaborator to the Company's board of directors. Total convertible senior notes - par Debt Instrument, Face Amount Repayments of Convertible Debt Repayments of Convertible Debt Debt Conversion, Converted Instrument, Shares Issued Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments Treasury Stock, Shares, Acquired Payments for Repurchase of Warrants Payments for Repurchase of Warrants Maximum amount of warrant payable Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Facilities Building [Member] Equipment Equipment [Member] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Facility Purchase Price Facility Purchase Price Agreed to purchase price for entire Tarrytown, New York facility, subject to certain customary adjustments. Payment towards purchase price of Tarrytown facility Payment towards purchase price of Tarrytown facility Payment towards purchase price of Tarrytown facility. A proportionate amount of which was recorded as a reduction of capital and facility lease obligations. Aggregate funding advanced by the participants Aggregate funding advanced by the participants Aggregate funding advanced by the participants, and used by Banc of America Leasing and Capital to acquire the Tarrytown facility. Reimbursement received by the Company Reimbursement received by the Company Reimbursement received by the Company upon closing of the purchase agreement. Initial term of lease Initial term of lease Initial term of lease Potential extended term of lease Potential extended term of lease Potential extended term of lease Tarrytown facility capital and facility lease obligations Tarrytown facility capital and facility lease obligations Capital and facility lease obligations recorded by the Company related to the Tarrytown facility. Interest expense in connection with capital and facility leases Interest expense in connection with capital and facility leases Interest expense in connection with capital and facility leases Commitments under operating leases [Abstract] Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] 2018 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2019 Operating Leases, Future Minimum Payments, Due in Two Years 2020 Operating Leases, Future Minimum Payments, Due in Three Years 2021 Operating Leases, Future Minimum Payments, Due in Four Years 2022 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total Operating Leases, Future Minimum Payments Due Rent expense under operating leases [Abstract] Operating Leases, Rent Expense, Net [Abstract] Rent expense under operating leases Operating Leases, Rent Expense, Net Tarrytown lease [Abstract] Tarrytown lease [Abstract] Tarrytown lease [Abstract] Schedule of Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Retirement Benefits [Abstract] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table] Entity by Location [Axis] Entity by Location [Axis] Location [Domain] Location [Domain] Geographic Distribution, Foreign [Member] Geographic Distribution, Foreign [Member] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items] Employer contribution expense to 401(k) Savings Plan Defined Contribution Plan, Cost Common Stock contributed to the Savings Plan (in shares) Marketable Securities Marketable Securities [Table Text Block] Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Credit Facility [Domain] Credit Facility [Domain] November 2016 Agreement [Member] [Member] November 2016 Agreement [Member] [Member] November 2016 Agreement repurchase of warrants February 2016 Agreement [Member] February 2016 Agreement [Member] February 2016 Agreement [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Debt Instrument, Face Amount Treasury Stock, Value Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Initial conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Net carrying amount of the liability component [Abstract] Net carrying amount of the liability component [Abstract] -- None. No documentation exists for this element. -- Treasury Stock, Shares Interest Expense, Debt [Abstract] Interest Expense, Debt [Abstract] Warrants [Abstract] Warrants and Rights Note Disclosure [Abstract] Reduction of number of warrants Reduction of number of warrants Reduction of number of warrants Adjustments to Additional Paid in Capital, Other Warrants and Rights Outstanding Warrants and Rights Outstanding Convertible Debt [Abstract] Convertible Debt [Abstract] Stock Issued During Period, Shares, New Issues Stock Issued During Period, Shares, New Issues Loss on Extinguishment of Debt Line of Credit Facility [Abstract] Line of Credit Facility [Abstract] Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Expiration Period Line of Credit Facility, Expiration Period Available increase to the credit facility Available increase to the credit facility Maximum available increase to the credit facility Line of Credit Facility, Current Borrowing Capacity Line of Credit Facility, Current Borrowing Capacity Line of Credit Facility, Fair Value of Amount Outstanding Line of Credit Facility, Fair Value of Amount Outstanding Treasury Stock, Value, Acquired, Cost Method Property, Plant and Equipment [Abstract] Property, Plant and Equipment Property, Plant and Equipment Disclosure [Text Block] Schedule of Quarterly Financial Information Quarterly Financial Information [Table Text Block] Unaudited Quarterly Results Quarterly Financial Information [Text Block] Commitments Under Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Rent Expense Under Operating Leases Schedule of Rent Expense [Table Text Block] Commitments under facility lease obligation Commitments under facility lease obligation [Table Text Block] Tabular disclosure of the commitments required in the aggregate and for each of the five succeeding fiscal years and thereafter under facility lease obligations having noncancelable lease terms. Payment [Axis] Payment [Axis] Payment [Axis] Payment [Domain] Payment [Domain] [Domain] for Payment [Axis] Additional payments received [Member] [Member] Additional payments received [Member] [Member] Additional payments received [Member] [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Collaborative Arrangement [Member] Collaborative Arrangement [Member] Collaboration revenue Collaboration revenue Revenue recognized in the period, inclusive of amounts recognized which were previously deferred. Schedule of assets measured at fair value on a recurring basis Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Legal Matters Legal Matters and Contingencies [Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Schedule of Long-term Debt Instruments Schedule of Long-term Debt Instruments [Table Text Block] Interest Expense Associated with Convertible Notes Convertible Debt [Table Text Block] Inventory Inventory Disclosure [Text Block] Accounts and Notes Receivable, Net Net product sales Net product sales [Table Text Block] Net product sales [Table Text Block] Schedules of Concentration of Risk, by Risk Factor Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Sales Related Deductions Activity Schedule of Sales Related Deductions Activity [Table Text Block] Tabular disclosure of the activity of sales-related deductions during the period, which may include rebates and chargebacks, and distributor-related fees. Intella Therapeutics [Member] Intella Therapeutics [Member] Intella Therapeutics [Member] Convertible Debt Debt Disclosure [Text Block] Income Taxes Income Tax Disclosure [Text Block] Long-Term Incentive Plans Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Revenue Disclosure [Table] Revenue Disclosure [Table] EYLEA EYLEA Net Product Sales [Member] Revenue during the period derived from a specified product line (EYLEA), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions. ARCALYST Arcalyst Net Product Sales [Member] Revenue during the period derived from a specified product line (ARCALYST), after deducting applicable provisions for discounts, returns, rebates, chargebacks, distribution fees, and other sales-related deductions. Besse Medical Besse Medical [Member] Besse Medical [Member] McKesson Corporation McKesson Corporation [Member] McKesson Corporation [Member] Curascript SD Curascript SD [Member] Curascript SD [Member] Minimum [Member] Maximum [Member] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer concentration risk Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Gross Sales Revenue GrossSalesRevenue [Member] GrossSalesRevenue [Member] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves [Domain] Valuation Allowances and Reserves [Domain] Rebates and Chargebacks Rebates and Chargebacks [Member] A valuation allowance for rebates and chargebacks under governmental programs (including Medicaid), which are netted against revenue from product sales. Distribution Related Fees Distribution Related Fees [Member] A valuation allowance for distribution-related fees which are netted against revenue from product sales. Other Sales Related Deductions Other Sales Related Deductions [Member] A valuation allowance for other sales-related deductions which are netted against revenue from product sales. Revenue Disclosure [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Concentration risk, percentage Concentration Risk, Percentage Activity of Sales Related Deductions [Roll Forward] Movement in Valuation Allowances and Reserves [Roll Forward] Balance Valuation Allowances and Reserves, Balance Provision related to current period sales Valuation Allowances and Reserves, Additions for Charges to Other Accounts Credits/payments Valuation Allowances and Reserves, Deductions Estimated useful lives of property, plant, and equipment [Table Text Block] Estimated useful lives of property, plant, and equipment [Table Text Block] Tabular disclosure of the estimated useful lives of property, plant, and equipment. Deferred Revenue, by Arrangement, Disclosure Deferred Revenue, by Arrangement, Disclosure [Table Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Classification of Investment [Axis] Classification of Investment [Domain] Gross Sales Revenue Accounts Receivable [Member] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Accounting Standards Update 2014-09 [Member] Accounting Standards Update 2014-09 [Member] Building and improvements Building and Building Improvements [Member] Laboratory and other equipment Furniture and Fixtures [Member] Furniture and Fixtures [Member] Cumulative Effect on Retained Earnings, Tax Cumulative Effect on Retained Earnings, Net of Tax Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Estimated useful life Property, Plant and Equipment, Useful Life Revenue Recognition [Abstract] Revenue Recognition [Abstract] Concentration Risks, Types, No Concentration Percentage [Abstract] Allowance for Doubtful Accounts Receivable, Current Allowance for Doubtful Accounts Receivable, Current Provision for Doubtful Accounts Provision for Doubtful Accounts Net Income (Loss) Per Share Earnings Per Share [Text Block] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] UNITED STATES UNITED STATES Foreign Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Income before income taxes Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Current Federal Tax Expense (Benefit) State Current State and Local Tax Expense (Benefit) Current Foreign Tax Expense (Benefit) Current Foreign Tax Expense (Benefit) Total current tax expense Current Income Tax Expense (Benefit) Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) State Deferred State and Local Income Tax Expense (Benefit) Deferred Foreign Income Tax Expense (Benefit) Deferred Foreign Income Tax Expense (Benefit) Total deferred tax (benefit) expense Deferred Income Tax Expense (Benefit) Total income tax expense (benefit) Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] U.S. federal statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Effective Income Tax Rate Reconciliation, Percent Effective Income Tax Rate Reconciliation, Percent Change in state effective rate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent State and local income taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Foreign income tax rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Income tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Percent Non-deductible Branded Prescription Drug Fee Effective Income Tax Rate Reconciliation, Deduction, Medicare Prescription Drug Benefit, Percent Domestic production activities deduction Effective Income Tax Rate Reconciliation, Deduction, Qualified Production Activity, Percent Other permanent differences Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent Components of Deferred Tax Assets and Liabilities [Abstract] Components of Deferred Tax Assets and Liabilities [Abstract] Deferred tax assets: Components of Deferred Tax Assets [Abstract] Deferred revenue Deferred Tax Assets, Deferred Income Deferred compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Fixed and intangible assets Deferred Tax Assets, Property, Plant and Equipment Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities Other Deferred Tax Assets, Other Deferred tax assets, gross Deferred Tax Assets, Gross Valuation allowance Deferred Tax Assets, Valuation Allowance Deferred tax assets, net Deferred Tax Assets, Net of Valuation Allowance Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Deferred Tax Liabilities, Property, Plant and Equipment Deferred Tax Liabilities, Property, Plant and Equipment Deferred Tax Liabilities, Other Deferred Tax Liabilities, Other Deferred tax liabilities, gross Deferred Tax Liabilities, Gross Deferred Tax Assets, Net Deferred Tax Assets, Net Utilization of net operating loss carryforwards related to exercises of Nonqualified Stock Options and disqualifying dispositions of ISOs, credited to additional paid-in capital Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Other Comprehensive Income (Loss), Tax Other Comprehensive Income (Loss), Tax Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Balance as of January 1 Unrecognized Tax Benefits Gross increases related to current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Unrecognized Tax Benefits, Period Increase (Decrease) Unrecognized Tax Benefits, Period Increase (Decrease) Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Balance as of December 31 Transactions Involving Stock Option Awards Share-based Compensation, Stock Options, Activity [Table Text Block] Weighted-Average Exercise Prices and Weighted-Average Grant-Date Fair Values of Options Issued Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Weighted-Average Values of Assumptions Used in Computing Fair Value of Option Grants Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Activity Related to Restricted Stock Awards Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Employee Savings Plan Pension and Other Postretirement Benefits Disclosure [Text Block] Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Schedule of Related Party Transactions Schedule of Related Party Transactions [Table Text Block] Schedule of Selected Financial Information - Sanofi Schedule of Selected Financial Information - Sanofi [Table Text Block] Schedule of selected financial information - Sanofi [Table Text Block] Collaboration revenue Collaboration revenue [Table Text Block] Summary of collaboration revenue [Table Text Block] Schedule of Selected Financial Information - Bayer Schedule of Selected Financial Information - Bayer [Table Text Block] Schedule of Selected Financial Information - Bayer [Table Text Block] Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Fair Value Estimate of Fair Value Measurement [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Measured on a recurring basis Fair Value, Measurements, Recurring [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Available-for-sale marketable securities: Available-for-sale Securities [Abstract] Financial Instruments, Owned, Corporate Debt, at Fair Value Financial Instruments, Owned, Corporate Debt, at Fair Value Financial Instruments, Owned, US Government and Agency Obligations, at Fair Value Financial Instruments, Owned, US Government and Agency Obligations, at Fair Value Municipal Debt Securities, at Carrying Value Municipal Debt Securities, at Carrying Value Commercial Paper Commercial Paper Certificates of Deposit, at Carrying Value Certificates of Deposit, at Carrying Value Available-for-sale Securities, Equity Securities Available-for-sale Securities, Equity Securities Marketable Securities, Unrealized Gain (Loss) Marketable Securities, Unrealized Gain (Loss) Fair Value, Assets, Level 2 to Level 1 Transfers, Amount Fair Value, Assets, Level 2 to Level 1 Transfers, Amount Fair Value, Assets, Level 1 to Level 2 Transfers, Amount Fair Value, Assets, Level 1 to Level 2 Transfers, Amount Proceeds from Sale and Maturity of Marketable Securities Proceeds from Sale and Maturity of Marketable Securities Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3 Basic and Diluted Net Income (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Antidilutive Securities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Accrued capital expenditures Accrued Capital Expenditures Carrying value as of the balance sheet date of obligations incurred and payable for purchases of fixed assets. Included in accounts payable and accrued expenses. Facility lease obligations recognized Capital and facility lease obligations recognized The capital and facility lease obligations recognized during the period. Statement of Cash Flows Cash Flow, Supplemental Disclosures [Text Block] Schedule of Property, Plant and Equipment [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Europe [Member] Europe [Member] Building [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Land, Gross Land Buildings and Improvements, Gross Buildings and Improvements, Gross Leasehold Improvements, Gross Leasehold Improvements, Gross Construction in Progress, Gross Construction in Progress, Gross Costs incurred by the landlord to construct new laboratory and office facilities Costs incurred by the landlord to construct new laboratory and office facilities Costs incurred by the landlord to construct new laboratory and office facilities which are included in PPE Furniture and Fixtures, Gross Furniture and Fixtures, Gross Property, plant, and equipment, gross Property, Plant and Equipment, Gross Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant, and equipment, net Depreciation Depreciation Capital and facility leases, at cost Capital and facility leases, at cost Property, plant, and equipment, at cost, of leased property under the Company's capital and facility leases. Depreciation and amortization expense Depreciation, Depletion and Amortization Accumulated amortization of capital and facility leases Accumulated amortization of capital and facility leases Accumulated amortization of capital and facility leases starting at sales achievement - $200 million sales achievement - 1st tier [Member] sales achievement - 1st tier [Member] sales achievement - 100 million sales achievement - 100 million [Member] [Member] sales achievement - 100 million [Member] [Member] Levels of twelve months sales at which sales milestone payments were received - 200 million Levels of twelve months sales at which sales milestone payments were received - 200 million In connection with a November 2013 agreement, the Company received additional sales milestone payments if twelve-month sales of specific commercial supplies of EYLEA outside the U.S. achieve certain specified levels up to this level. maximum advance notice required to terminate collaboration agreement maximum advance notice required to terminate collaboration agreement maximum advance notice required to terminate collaboration agreement Schedule of Capital Leased Asssets [Table] Schedule of Capital Leased Assets [Table] Capital Leased Assets [Line Items] Capital Leased Assets [Line Items] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Non-cash compensation expense Share-based Compensation Other non-cash charges and expenses, net Other Noncash Income (Expense) Deferred Taxes Increase (Decrease) in Deferred Income Taxes Changes in assets and liabilites Increase (Decrease) in Operating Capital [Abstract] Increase in Sanofi, Bayer, and trade accounts receivable Increase (Decrease) in Accounts Receivable Increase in Inventories Increase (Decrease) in Inventories (Increase) decrease in prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets (Decrease) increase in deferred revenue Increase (Decrease) in Deferred Revenue (Decrease) increase in accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Total adjustments Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of marketable and other securities Sales or maturities of marketable securities Capital expenditures Payments to Acquire Productive Assets Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds in connection with capital and facility lease obligations Proceeds from (Repayments of) Long-term Debt and Capital Securities Payments in connection with capital and facility lease obligations Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities Repayments of convertible senior notes Payments in connection with reduction of outstanding warrants Proceeds from issuance of Common Stock Proceeds from Issuance of Common Stock Payments in connection with Common Stock tendered for employee tax obligations Payments Related to Tax Withholding for Share-based Compensation Excess Tax Benefit from Share-based compensation Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash paid for interest (net of amounts capitalized) Interest Paid, Net Cash paid for income taxes Income Taxes Paid, Net